# Desmopressin acetate (DDAVP)

| | | |
|---|---|---|
| Desmopressin dosing may be weight based; ensure accuracy of documented weight before administration | | |
| **Form & Storage** | 4 microgram in 1 mL vial | Store at 2–8°C in original packaging. |
| **Reconstitution** | Already in solution | |
| **Compatibility & Stability** | Sodium chloride 0.9% | |
| **Administration** | **IV Infusion** | |
| | Add required dose to 50 mL of Sodium Chloride 0.9%<br>Infuse over 20-30 minutes, choose a large vein and monitor infusion site closely. | |
| | **IV Injection** | |
| | Withdraw required dose<br>Give slowly over 3-5 minutes using a large vein. | |
| | **IM Injection** | |
| | Allow to reach room temperature before giving by IM injection.<br>Withdraw required dose. Administer undiluted.<br>Small doses e.g. 400nanograms (0.1mL) or less may be diluted in sodium chloride 0.9% for ease of administration. | |
| | **SC Injection** | |
| | Withdraw required dose<br>Give by SC injection | |
| **Monitoring** | Monitor BP and pulse continuously during IV Infusion<br>Body weight (or plasma sodium or osmolality) to check for fluid overload with repeated administration | |
| **Extravasation** | Extravasation, is likely to cause tissue damage because of the pH of the solution. | |
| **Additional Information** | • It is recommended to maintain fluid and electrolyte balance. Treatment without concomitant reduction of fluid intake may lead to fluid retention and/or hyponatremia with or without accompanying warning signs and symptoms.<br>• When used for **diagnostic purposes** the fluid intake must be limited to a maximum of 0.5 L to quench thirst from 1 hour before until 8 hours after administration.<br>• Oral, intranasal, intravenous, subcutaneous and intramuscular doses are expressed as desmopressin acetate; sublingual doses are expressed as desmopressin base.<br>• Desmopressin acetate 1 microgram approx equal to desmopressin 0.9 microgram.<br>• See below CUH-PPG-C-PHA-20 **Management of bleeding following insertion of tunnelled vascular catheters and to prevent bleeding during renal biopsy Protocol** | |

**Information provided relates to DDAVP® manufactured by Ferring Pharmaceuticals Ltd**

# Management of bleeding following insertion of tunnelled vascular catheters and to prevent bleeding during renal biopsy

| | |
|---|---|
| **Dose of Desmopressin as Desmopressin Acetate (DDAVP®)** | 0.3 to 0.4microgram/kg IV (usual maximum of 20 microgram, doses >40mcg have not been reported for bleeding indications)[2,3] |
| **Form** | 4 microgram Desmopressin in 1 ml ampoule (4 microgram/ml) |
| **Reconstitution** | Already in solution<br>Further dilute before administration |
| **Administration** | **IV Infusion** |
| | Dilution for intravenous infusion<br>• Add required dose to 50 ml of Sodium Chloride 0.9%<br>• Infuse over 30 minutes<br>• See CUH Adult Intravenous Guidelines for monograph for further information |
| **Pharmacokinetics** | • Onset of action less than one hour[2]<br>• Duration of effect 4-8hours[2] |
| **Compatibility & Stability** | Sodium Chloride 0.9% only |
| **Special Notes** | • Vial should be stored in the fridge (2-8˚C)<br>• Patients with renal impairment: dose as in normal renal function<br>• Patients undergoing renal replacement therapies: unlikely to be dialysed<br>• These are unlicensed indications<br>• See SPC for full prescribing information |

**Information relates to DDAVP® manufactured by Ferring Pharmaceuticals**

References


1. DDAVP®/Desmopressin, Summary of Product Characteristics, Ferring Pharmaceuticals – https://www.hpra.ie
2. The Renal Drug Database -https://renaldrugdatabase.com. Accessed on: 19/06/23
3. Up to date- www.uptodate.com. Accessed on: 19/06/23